Hepatoprotection with clinically proven antioxidant molecules & micronutrients in chronic liver diseases (CLDs)– A new promise in clinical practice.

PROLIVA

The liver has multiple functions and is the principal detoxifying organ, acting in the clearance of pathogens, toxic chemicals and metabolic waste products from the body, also contributing, for the adequate function of other organs. It impacts heavily almost all physiologic systems to maintain homeostasis. The continuous exposure of the liver to some factors, such as viruses, alcohol, fat, biotransformed metabolites, among others, can cause hepatic injury, which can lead to inflammation and liver degeneration. When the injury is sustained for long time, it can cause chronic liver diseases (CLDs), which occur in multistage processes of fibrosis, cirrhosis and hepatocellular carcinoma (HCC).

The liver is made up of hepatocytes, Kupffer cells, liver sinusoidal endothelial cells, pit cells, and hepatic stellate cells (HSC). Liver fibrosis is a wound healing process, which is reversible and results from chronic liver injuries, including those caused by alcohol consumption, chronic viral hepatitis, autoimmune diseases, parasites, metabolic diseases, lipopolysaccharide (LPS) and other toxins or drugs. In these cases, generally, the inflammation is the first phase, and develops to fibrosis due to increased hepatic necrosis and activation of hepatic stellate cells after chronic oxidative stress (OS). When fibrosis is not controlled, it can progress into cirrhosis and after to HCC. Alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD) and chronic viral hepatitis (B and C), are the three most common causes of liver cirrhosis.

For this reason, to prevent and treat chronic liver diseases (CLDs) with progressive fibrosis, the application of molecules with antioxidant, anti-inflammatory and hepatoprotective properties as adjuvant/adjunctive therapy with the etiological treatment is a new trend in modern clinical medicine not only due to their low toxicity profile but also very promising therapeutic effects. Proliva 1.3g tablet is an advanced liver care formula that contains biologically active natural compounds (Glycyrrhizic acid and Curcuminoids), antioxidants (Alpha-Lipoic acid, Coenzyme Q10) and clinically proven micronutrients (L-Carnitine, L-Arginine, L-Glycine, L-Methionine, N-Acetylcysteine, Pyridoxine, Calcium pantothenate, Folic acid, Selenium and Zinc etc.) for its hepatoprotective, antioxidant, anti-inflammatory, , choleretic, detoxifying and anti-fibrotic activities. A large number of studies have demonstrated that the biologically active natural compounds, antioxidants and clinically proven micronutrients present in Proliva are capable of inducing anti-apoptotic effect of healthy hepatocyte, apoptotic stimulating effect of hepatic stellate cells (HSC), hepatocyte proliferating effect and stabilizing effect of hepatic cellular membranes which are potential for “Anti-fibrotic Activity”. Different human trials also demonstrated the promising clinical effects of such agents present in Proliva in improving histological, biochemical and metabolic parameters in different Chronic Liver Diseases (CLDs).